肾炎康对大鼠系膜增生性肾炎MCP-1的影响

目的:探讨中药肾炎康对大鼠系膜增生性肾炎(MsPGN)模型病理及尿中单核细胞趋化蛋白-1(MCP-1)的影响。方法:采用大鼠慢性血清病性MsPGN模型。于造模第6周随机分为肾炎康组及模型组,肾炎康组每日灌服肾炎康3ml,模型组每日灌服等量自来水。42天后,观察两组大鼠尿MCP-1及尿蛋白水平,BUN、Scr及肾脏病理改变。结果:模型组尿MCP-1、尿蛋白量、BUN及Scr均显著高于正常对照组(P均<0.01)。病理检查见肾小球肿大,系膜细胞及基质弥漫性增殖,肾小球内及肾间质炎性细胞浸润。肾炎康组尿MCP-1、尿蛋白、BUN及Scr虽亦高于对照组(P<0.05～0.01),但显著低于模型组(P<0.05～0.01)。肾脏病理改变明显比模型组轻,系膜轻度或节段增殖,炎性细胞浸润轻。结论:肾炎康能减轻MsPGN系膜细胞增殖及炎症细胞浸润,减轻病理改变,改善肾功能,降低尿中MCP-1及尿蛋白,因而对MsPGN有治疗作用,其机制可能与抑制MCP-1有关。

Effect of Shenyankang on MCP-1 of Rats with MsPGN

Objective:To obverse the effect of Shenyankang on pathology and MCP-1 in urine of rats with MsPGN.Methods:Rats with MsPGN were randomly divided into the Shenyankang group and the model group.The Shenyankang group was treated by Shanyankang with 3ml/d orally and the contrast group by water with same volume each day.The level of MCP-1 and albumen in urine,BuN,Scr and variety of nephric pathology were observed after therapy for 42 days.Results:The level of MCP-1 and albumen in urine,BuN and Scr in the model group were obviously higher than those in the normal contrast model(P<0.01)with intumescent glomerulus,proliferous membrane and permeant inflammatory cell.The level of MCP-1 and albumen in urine,BuN and Scr in the Shyankang group were higher than those in the contrast group(P<0.05~0.01),but significantly lower than those in the model group(P<0.05~0.01)with light variety of nephric pathology and low degree of proliferous membrane and permeant inflammatory cell.Conclusion:Shenyankang can relieve the proliferous membrane and permeant inflammatory cell,lighten the variety of nephric pathology,improve the function of kidney and decrease the level of MCP-1 and albumen in urine.It has curative effect on treating MsPGN.The mechanism maybe relate to the prohibition of MCP-1.